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Abstract 
Background 
Recently, a possible correlation between atypical femur fractures and long-term use of 
bisphosphonates has been found. Thigh pain and radiographic skeletal changes are possible 
prodromal symptoms and findings. 
Objective 
The aim of the current study was to elucidate if prodromal thigh pain could be could be used 
as a screening tool to find patients at high risk of atypical femoral fractures in patients with 
low BMD measured by the Osteoporosis centre at the Orthopaedic department of Oslo 
University Hospital Ullevål. 
Methods 
All available DEXA-data at Oslo University Hospital Ullevål were collected. We included 
patients who had T-score equal to or lower than -2.5 and searched their journals for available 
information on fracture history, drug history, bisphosphonate use, and DEXA-data. Patients 
were interviewed by telephone in order to complete the data. We used multivariable binary 
logistic regression and Pearson’s Chi-Square test to test correlation between thigh pain and 
other factors. 
Results 
DEXA-data provided us with 338 patients, of which 120 were included. 9 patients reported 
thigh pain, of which one already had experienced an atypical femur fracture. The other 
patients had pain related to other illnesses. Specificity of bone pain is 11%. We found a 
correlation between thigh pain and age (p = 0.003, 95% CI 1.06-1.13) but no correlation to 
length of bisphosphonate use (p = 0.112, 95% CI 0.99-1.07), nor other drugs affecting bone 
metabolism (p = 0.196, 95% CI 0.48-35.49). 
Conclusion 
Thigh pain asked by telephone is an unspecific symptom. Previous studies imply that caution 
should be maintained when the duration of bisphosphonate therapy exceeds 4-5 years. 
Examination of bone mineral density should be performed, the continuation of 
bisphosphonate therapy should be re-evaluated and the physician should consult the patient 
regarding thigh pain. Patients should also be informed about atypical femur fractures so that 
they can contact a physician for clinical and radiographic examination if thigh pain occurs. 
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Background 
Norwegians suffer 9,000 hip fractures and 15,000 distal radius fractures each year. Norway 
and other Scandinavian countries have the highest incidence of hip fractures in the world. 
Osteoporosis is a major contributing risk factor (1).  
Osteoporosis – diagnosis and therapy  
According to WHO guidelines osteoporosis is defined as Bone Mineral Density (BMD) equal 
to or lower than 2.5 standard deviations from the expected value of a young adult, of the same 
sex and ethnicity (2). BMD is usually measured by Dual-Energy X-ray Absorptiometry 
(DEXA).  
DEXA is a technique in which X-rays are generated in two energy levels in one plane. DEXA 
measures the Bone Mineral Content (BMC) and the Bone Area (BA), and thus calculates the 
BMD. The BMD value itself is not usually used as a measure in the clinic. Physicians use the 
T-score to evaluate the bone mass (3). The T-score describes the number of standard 
deviations between the patient’s BMD and the expected BMD of a young adult-population. 
The WHO classification is given in table 1 (2): 
 Normal Osteopenia (low bone mass) Osteoporosis Established osteoporosis 
T-score ≥1 < -1 og >-2.5 ≤ -2.5 ≤-2.5 
Additional condition    Fragility fracture 
Table 1: The WHO osteoporosis classification  
 
Patients with established osteoporosis, which is T-score ≤ -2.5 with the presence of a fragility 
fracture, are usually treated medically. According to guidelines (4;5), the first choice of 
medical treatment is bisphosphonates, primarily alendronate 70 mg weekly, combined with 
calcium (800-1,000 mg) and vitamin D (400-800 units) (4). Alternative bisphosphonates are 
risedronate 5 mg daily, ibandronate 50 mg daily and zoledronic acid 5mg yearly. The 
guidelines do not specify duration of the bisphosphonate treatment (5;6). Long term-treatment 
is not well defined in literature, but > 5-6 years is usually used. 
Bisphosphonates – pharmacology, clinical use and side effects 
Bisphosphonates are analogues of pyrophosphate. They bind to hydroxyapatite, one of the 
building blocks of bone, which gives bisphosphonates an effect that’s mainly bone-specific. 
Bone undergo a constant maintenance process called bone remodelling or bone turnover, 
where osteoclasts resorb the bone and the osteoblasts reform it. When osteoclasts begin to 
resorb bone that is impregnated with bisphosphonate, the bisphosphonate is released to the 
osteoclasts. They impair bone resorption by reducing the osteoclasts’ ability to form the 
ruffled border, to adhere to the bony surface, and to produce acid. In addition they also reduce 
differentiation of the osteoclasts’ progenitor cells and induce apoptosis. Because resorption 
and reformation are coupled processes, it is believed that use of bisphosphonates reduces the 
total bone turnover through its inhibitory effect on osteoclasts (7). 
Bisphosphonates have several areas of use, e.g. osteoporosis, hypocalcaemia, early breast 
cancer, prostate cancer metastasis, multiple myeloma, skeletal metastasis, Paget’s disease and 
osteogenesis imperfecta (7). Bisphosphonates has been characterised as a drug with few side 
effects, the most common being stomach pain (8).  
The most common side effects include Flu-like symptoms, which are common after 
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intravenous infusion and usually lasts 24-74 hours; musculoskeletal pain, kidney failure and 
hypocalcaemia (6;9). These are rare in patients with normal kidney function, but 
bisphosphonates are not recommended if the patient’s creatinine clearance is below 30-35; 
Ocular toxicities including conjunctivitis, uveitis, scleritis, and orbital inflammation are very 
rare.  
Osteonecrosis of the jaw (ONJ) has been discussed as a possible side effect of 
bisphosphonates, but has almost exclusively appeared in patients with terminal cancer and use 
of bisphosphonates for treating hypercalcaemia or skeletal metastases, and seems to be a very 
rare side effect when treating primary osteoporosis (6;9). Another feared side effect is 
oesophageal ulcers, but it is usually prevented by following the instructions for the tablets (6). 
Subtrochanteric low energy fractures – a side effect? 
In 2005 Odvina et al. (10) presented the first case series of patients on bisphosphonates 
suffering from low and ultra-low energy femoral shaft fractures. In 2007 Goh et al. presented  
the first retrospective study on subtrochanteric low energy femoral shaft fractures where they 
suggested an association between the fractures and the long term use of bisphosphonates (11). 
In the recent years several case series (12-21) and retrospective studies (11;22-25) have 
continued to investigate and point out the statistical association between long term use of 
bisphosphonates and low energy fractures in the subtrochanteric and diaphyseal region of the 
femur. Neviaser et al. calculated that the usage of bisphosphonates was a significant risk 
factor for the fracture (OR 139.3, 95% CI 19.0-939.4). Giusti et al.(23) got a similar result 
(OR 17.00, 95% CI 2.55-113.26). Isaacs et al. and Lenart et al., using the same case material, 
have shown that patients suffering from the fractures had a significantly longer use of 
bisphosphonates compared to patients with other fractures. (Isaacs et al: 7.1 years vs. 3.2 
years, Lenart et al: 7.3 years vs. 2.8 years). The fracture case with the shortest use of 
bisphosphonates, 1.5 years, was reported by Lee et al.(13).  
Animal studies (26;27) have pointed out that bisphosphonates reduce bone turnover and may 
induce the accumulation of microdamage. Biopsy studies of human patients on 
bisphosphonates show a tendency of reduced bone turnover, but demonstrate variable results 
considering microdamage, and usually normal bone is found. A biopsy study by Armamento-
Villareal et al. (15) with 15 patients on bisphosphonates  with cortical fractures in different 
bones demonstrated that low bone turnover was more frequent with patients using 
bisphosphonates, but it did not show a difference in bone mineral density. They suggested that 
there might be a congenital risk factor which contributes to the fractures.  
In the Norwegian drug description (8), subtrochanteric low energy fractures are included 
under the title  ”very rare side effects” (<1/10.000), named ”stress fracture in the upper part of 
the femoral shaft”, but it is not included in the description of other bisphosphonates: 
etidronate (28), risedronate (29), pamidronate (30) and zoledronate (31). 
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Figure 1. X-ray pattern of the fracture: A 
horizontal fracture line and a medial cortical 
spike. Notice the thickened lateral cortex. 
 
Radiographic fracture pattern and nomenclature 
The fracture pattern (figure 1) of the supposedly 
bisphosphonate-induced subtrochanteric low 
energy fractures is characterised by a lateral 
horizontal fracture line, increased lateral cortical 
thickness and a medial cortical spike (19). Some 
studies have not included radiographic descriptions 
at all (10) and others studies, while having 
radiographic descriptions, did not mention this 
pattern (15;26;27). 
The name of the fracture varies in the literature. 
• Atypical femoral fracture (20;23)  
• Subtrochanteric stress fracture (12) 
• Subtrochanteric insufficiency fractures (11)  
• Low-energy femoral shaft (14;16;22;24;32) 
• Subtrochanteric femoral stress fractures 
(18) 
• Femoral insufficiency fracture (25) 
Associated symptoms and clinical findings 
Koh et al. (33) investigated the connection between 
the long term use of bisphosphonates, 
subtrochanteric fractures and radiographs. They 
found 4 patients with radiographs before the 
fracture, and all of them had a cortical stress lesion 
which they named dreaded black line (figure 2), a 
thin black line in a thickened lateral cortex. These 4 
patients also experienced thigh pain in the affected 
leg. The term dreaded black line is originally a 
radiographic finding on cortical stress fractures of 
the anterior tibia, which often advances into a 
complete fracture (34). 
Prodromal thigh pain has been reported by many 
papers. This has raised a question on whether it may 
be a symptom of a non-dislocated fracture. In the 
task force report for ASMBR Shane et al. (35) found 
thigh pain in 70% (158 of 227). Dell et al. (36) have 
in their study found thigh pain among 67% of their 
patients.  
There has also been reported several cases of 
bilateral fractures, including cases where both 
femurs fractured simultaneously or a second femur 
fracture soon after the first. Shane et al. (35) found 
pain to be bilateral in 28% (60 of 215) in their task 
Figure 2.  A dreaded black line in the lateral 
cortex with a localised periostal reaction. This 
could be a partial fracture which could advance 
into a complete fracture. The patients usually 
experience strong pain when straining the 
affected leg. 
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report, whilst Dell et al. (36) found bilateral pain in 25.9% among 135 patients. 
 
Later studies 
IOF (International Osteporosis Foundation) and ESCEO ( European Society on Clinical and 
Economic Aspects of Osteoporosis and Osteoarthritis) published in November 2010 a 
summary of all existing literature concerning the question (37). They conclude with that direct 
causality between bisphosphonates and subtrochanteric low energy fractures has yet to be 
established and that there is a need to do extensive pathological, epidemiological and clinical 
research on the issue. Use of bisphosphonates does not need to be limited, but physicians need 
to be attentive to long term-users of bisphosphonates. They conclude that the benefit of 
bisphosphonate therapy greatly outweighs the side effects.  
Shane et al. (35) released a task force report on behalf of The American Society for Bone and 
Mineral Research. They also conclude with the need for more research on different aspects of 
the problem, but still recommend using bisphosphonates as a treatment for osteoporosis. They 
also proposed a definition of major and minor features of the fractures (table 2): 
Atypical Femoral Fracture: Major and Minor Featuresa 
Major featuresb 
 • Located anywhere along the femur from just distal to the lesser trochanter to just proximal to the 
supracondylar flare 
 • Associated with no trauma or minimal trauma, as in a fall from a standing height or less 
 • Transverse or short oblique configuration 
 • Noncomminuted 
 • Complete fractures extend through both cortices and may be associated with a medial spike; 
incomplete fractures involve only the lateral cortex. 
Minor features 
 • Localized periosteal reaction of the lateral cortexc 
 • Generalized increase in cortical thickness of the diaphysis 
 • Prodromal symptoms such as dull or aching pain in the groin or thigh 
 • Bilateral fractures and symptoms 
 • Delayed healing 
 • Comorbid conditions (eg, vitamin D deficiency, RA, hypophosphatasia) 
 • Use of pharmaceutical agents (eg, BPs, GCs, PPIs) 
 
a) Specifically excluded are fractures of the femoral neck, intertrochanteric fractures with spiral subtrochanteric 
extension, pathologic fractures associated with primary or metastatic bone tumors, and periprosthetic fractures. 
b) All major features are required to satisfy the case definition of atypical femoral fracture. None of the minor 
features are required but sometimes have been associated with these fractures. 
c) Often referred to in the literature as beaking or flaring. 
Table 2: Diagnostic criteria for atypical femur fractures by the ASMBR task force (35). 
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Schilcher et al. (38) published in 2011 a study based on the entire Swedish female population. 
They established an age-adjusted absolute risk of 0.0005 and relative risk of 47.3 with any 
bisphosphonate use for sustaining an atypical femoral fracture in bisphosphonate users. In 
their case-control study they established that the risk of an atypical fracture was higher with 
an increasing duration of bisphosphonate use, with an odds ratio of 1.3 (95% CI, 1.1 to 1.6) 
per 100 daily doses prescribed. They also establish an incidence of 59 atypical femur fractures 
among 1.5 million Swedish women aged 55 or more. Among them, 46 used bisphosphonates. 
In total, there were 83 311 female bisphosphonate users aged 55 or more. 
Objective 
The aim of the current study was to elucidate if prodromal thigh pain, could be used as a 
screening tool to find patients at high risk of atypical femoral fractures in patients with low 
BMD measured by the Osteoporosis centre at the Orthopaedic department of Oslo University 
Hospital. We wanted to investigate if any of our osteoporosis patients had thigh pain and if 
that thigh pain could correspond to radiographic skeletal changes induced by bisphosphonate 
use.  
Methods 
1. We collected all available DEXA-data from Oslo University Hospital (OUS), Ullevål. 
The database had measurements from Feb 2004 until Jan 2011. All measurements past 
Dec 31st 2008 were excluded because of short follow-up. Only measurements of Total 
femur and Total spine (L1-L4) were included. Measurements with T-scores over -1.5 
were not included. The measurements were then grouped into 2 groups: Osteoporosis 
included patients with at least one T-score measurement below or equal to -2.5 and 
osteopenia included patients with T-score between –2.5 and –1.5. If a patient had two 
or more measurements of the same area in one day, we included only the latter of the 
two measurements. Information from the database are patient ID, birth date, name, 
date of measurement and T-score for spine and femur. 
2. We searched through the patient journals and collected information regarding 
fractures, recommendations of bisphosphonate use and side effects where available. 
3. All patients were interviewed by telephone and the following information were 
collected: 
o Bisphopshonates: 
 Which bisphosphonate does the patient use? 
 Does the patient use it correctly? 
 When did the patient initiate bisphosphonate treatment? 
 How long has the patient used bisphosphonates? 
o Has the patient experienced any side effects from bisphosphonate therapy? 
o Has the patient experienced thigh pain after initiating bisphosphonates?  
 Is the pain bilateral? 
 How severe is the pain? VAS-score was utilized. 
o Does the patient use other medications, emphasizing: 
 Hormone therapy 
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 Glucocorticoids 
 Antiepileptics 
 Aromasine inibitors 
 Calcium and vitamin D 
o Has the patient experienced any fractures after initiating bisphosphonate 
therapy? 
 
Patients with thigh pain were offered a consultation at the Department of Orthopaedics, OUS 
Ullevål. 
We used binary logistic regression to investigate the correlation between pain and length of 
bisphosphonate use, Pearson’s Chi-square test to investigate correlations between pain and 
other factors. All calculations were done by PASW Statistics ver. 18. 
Results 
The DEXA data set gave us 338 patients, among them 294 women and 45 men. 218 were 
excluded (figure 3).  
 
 
338 patients 
294 women 
45 men 
 
120 included 
103 women 
17 men 
 
218 excluded 
190 women  
28 men 
58 
deceased 
10 did not 
participate 
20 
unavailable 
9 had used BPs  
< 24 months 
6 had 
communicational 
difficulties 
5 quit therapy 
because of adverse 
effects 
4 did not 
want to use 
BPs 
16 were not 
recommended BPs 
by their physicians 
82 
unknown 
causes  
2 had low renal 
function 
4 other 
reasons 
111 did not 
use BPs 
2 uses 
teriparatide  
Figure 3: Excluded patients 
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Among the 120 included there were 103 females and 17 males. The mean age was 67, range 
35 to 90. 73% of the patient had experienced fractures earlier, 21% confimed no previous 
fractures and 7% were unknown. 17% of the patients had breast cancer. 24% uses drugs that 
affect bone metabolism (corticosteroids, hormone replacement therapy, aromasine inhibitors), 
whilst 73% of the patients were on other medications in addition to alendronate; not counting 
calcium and vitamin D supplements. Mean duration of bisphosphonate use was 56 months. 
Most patients used alendronate (88%) (table 3). 
 Frequency Percent 
Alendronate 106 88.3 
Zoledronate 11 9.2 
Risedronate 1 0.8 
Ibandronate 2 1.7 
Table 3: Distribution of bisphophonates. 
 
9 patients reported of leg pain (table 4). Clinical examination and radiographs of the femurs 
did not reveal bisphosphonate-induced skeletal changes like dreaded black lines or atypical 
femur fractures with patient 2-9. Thigh pain specificity in our case is 1/9 = 11 %. 
Patient Age Sex BP BP time 
(months) 
Pain 
(VAS) 
Location Cancer 
mammae 
Bone 
affecting 
medicatio
ns 
Other 
drugs 
1a 82 F Risedronate 56 50 Unilateral No No Yes 
2 90 F Alendronate 83 15 Unilateral No No Yes 
3 82 F Alendronate 138 45 Bilateral No No Yes 
4 83 F Zoledronate 45 20 Unilateral No No Yes 
5 65 F Zoledronate 42 35 Bilateral Yes Yesb Yes 
6 81 F Alendronate 76 50 Bilateral No No Yes 
7 87 F Alendronate 44 45 Unilateral No No Yes 
8 81 F Alendronate 59 40 Unilateral No No Yes 
9 60 F Zoledronate 75 15 Bilateral Yes Yesb Yes 
Table 4: Description of the patients who has experienced thigh pain 
a) Patient 1 has experienced a radiographically confirmed atypical femur fracture. She used alendronate 
for 1-2 weeks before changing to risedronate due to oesophageal ulcers. She used bisphosphonates for 
more than 4.5 years. She had prodromal thigh pain for 1-2 weeks before the fracture. 
b) Patient 5 and 9 used aromasine inhibitors. 
Binary logistic regression (table 5) was used to investigate if thigh pain could be correlated to 
age, length of bisphosphonate use and usage of drugs affecting bone metabolism. Each 
variable was investigated in a univariate model and in a multivariable model incorporating all 
three (table 4). Sex was not included because no male patients experienced thigh pain.  
Variable Univariable model Multivariable model 
P-value Odds ratio, 95% CI P-value Odds ratio, 95% CI 
Lower Upper Lower Upper 
Age 0.002 1.057 1.271 0.003 1.058 1.312 
Length of 
bisphosphonate use 
0.073 0.998 1.055 0.112 0.993 1.067 
Usage of other drugs 
affecting bone 
metabolism 
0.776 0.153 4.052 0.196 0.481 35.488 
Table 5: Results of the binary logistic regression. 
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Discussion 
We found no new atypical femoral fractures or bisphosphonate induced skeletal changes with 
our strategy. We think there are at least three reasons for this. Firstly, it could be due to the 
combination of a rare phenomenon and a small study population. Secondly, it could have been 
that the observation period was short and our patients had yet to develop long term 
complications. The timing of a telephone interview may also be a problem. Patients 
experience thigh pain a limited time before the atypical fracture and telephone interview will 
most likely not coincide with that period. Thirdly, it could have been due to the method of 
detection; the interview did not differentiate patients with regards to the pattern of their pain 
history; e.g. one patient had a previous periprosthetic femoral fracture which caused chronic 
thigh pain.  
Our study shows no significant correlation between thigh pain and length of bisphosphonate 
use, but there is a trend in our data. Age is as expected correlated to thigh pain, but there was 
no correlation between age and length of bisphosphonate use. We think that it is natural for 
pain to accumulate among the elderly considering number of diseases and length of exposure 
to different risk factors that may contribute to a disease causing pain in the thigh region. 
Schilcher et al. (38) reported a number needed to harm of 2,000. It was thus not expected to 
find new diagnoses of bisphosphonate-induced skeletal changes. We did however find one 
patient that had already experienced an atypical femoral fracture. Even though the patient did 
experience thigh pain prior to the fracture it is uncertain whether it could have been detected 
by a telephone interview. 
Shane et al. (35) reported of a 70% prevalence of prodromal thigh pain among all the fractures 
in their task force report, but there were no numbers on the specificity of the symptom.  In our 
case we found it to be 11%, but considering the small number of patients we had in our study 
and the NNH (needed to harm) of 2000 per year of use calculated in the study by Schilcher et 
al. (38), the specificity is probably lower.  
Black et al, the authors of FIT (39-41), FLEX (42), and HORIZON-PFT (43), randomised 
controlled studies on the effect of bisphosphonates, have investigated the incidence of 
fractures in their patients. In 14.195 female patients, 284 patients developed fractures of the 
hip and the femur. There were 10 patients with a total of 12 subtrochanteric low energy 
fractures. Comparison proved no difference between the patients who received 
bisphosphonates and those who received placebo (44). There are two major weaknesses of 
this study. First is the lack of radiographs, which makes it difficult to evaluate the result. 
Second, there were only about 1000 patients in this study who had taken bisphosphonate over 
4.5 years. 
In a cohort by Kim et al, a comparison was performed between the incidence of all 
subtrochanteric and diaphyseal fractures in patients using bisphosphonates and in patients 
using raloxifene or calcitonin. They could not prove a difference (HR 1.03, 95% CI 0.70-1.52) 
(45). This study also lacks radiographs. 
A potential confounding factor when studying the fracture-inducing property of 
bisphosphonates may be the inclusion of patients on glucocorticoids (10;11;15;16;23). 
Glucocorticoids increases fracture risk (46).   
Some studies have questioned some of the proposed mechanism behind the atypical femur 
fractures; in one case Jamal et al. (47) reported a patient with bilateral atypical femur fractures 
with normal bone turnover. Somford et al. (48) could in another case not find increased 
mineralization in a patient with bilateral atypical femur fractures. Yates et al. (49) reported a 
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possible contributing factor , with a case study of a 35-year-old patient with pycnodysostosis, 
who suffered an atypical femur fracture without a history of osteoporosis therapy.  
Our study has several limitations. The number of patients was too low to expect statistically 
significant results given a low specificity of thigh pain as a symptom of bisphosphonate 
induced skeletal changes in a telephone interview. We attempted to do a set of Pearson’s Chi-
square tests, but the results are not reliable due to several individual expected frequencies with 
low values.  
Conclusion 
We found 9/120 patients who had experienced thigh pain. We did not find a relationship 
between length of bisphosphonate therapy and thigh pain, but this suggests that thigh pain in a 
telephone setting is an unspecific symptom.  
In our opinion, physicians should not stop prescribing bisphosphonates to patients diagnosed 
with osteoporosis; the benefits by far outweigh the disadvantages. The case finding strategy 
we chose has a limited value until a better definition of high risk patients and perhaps better 
ways of elucidating symptoms by phone have been found. Caution should be maintained 
when the length of bisphosphonate therapy exceeds 4-5 years. Examination of bone mineral 
density should be performed, the continuation of bisphosphonate therapy should be re-
evaluated and the patient should be asked of thigh pain. Patients should also be informed 
about atypical femur fractures so that they can contact a physician for clinical and 
radiographic examination if thigh pain occurs. 
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